Abstract

Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders. Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls. All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease. Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD. We found significant associations between macular thickness and global cortical atrophy [β −0.358; P =.01] and parietal cortical atrophy on magnetic resonance imaging [β −0.371; P <.01] in AD cases. Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.
Original languageEnglish
Pages (from-to)463-471
Number of pages9
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume11
DOIs
Publication statusPublished - 2019

Cite this

@article{43452a5e2e364fc7b40be8c682c1e5a7,
title = "Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease",
abstract = "Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders. Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls. All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease. Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD. We found significant associations between macular thickness and global cortical atrophy [β −0.358; P =.01] and parietal cortical atrophy on magnetic resonance imaging [β −0.371; P <.01] in AD cases. Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.",
author = "Haan, {Jurre den} and {van de Kreeke}, {Jacoba A.} and Elles Konijnenberg and Kate, {Mara ten} and Braber, {Anouk den} and Frederik Barkhof and {van Berckel}, {Bart N.} and Teunissen, {Charlotte E.} and Philip Scheltens and Visser, {Pieter Jelle} and Verbraak, {Frank D.} and Bouwman, {Femke H.}",
year = "2019",
doi = "10.1016/j.dadm.2019.05.002",
language = "English",
volume = "11",
pages = "463--471",
journal = "Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease

AU - Haan, Jurre den

AU - van de Kreeke, Jacoba A.

AU - Konijnenberg, Elles

AU - Kate, Mara ten

AU - Braber, Anouk den

AU - Barkhof, Frederik

AU - van Berckel, Bart N.

AU - Teunissen, Charlotte E.

AU - Scheltens, Philip

AU - Visser, Pieter Jelle

AU - Verbraak, Frank D.

AU - Bouwman, Femke H.

PY - 2019

Y1 - 2019

N2 - Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders. Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls. All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease. Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD. We found significant associations between macular thickness and global cortical atrophy [β −0.358; P =.01] and parietal cortical atrophy on magnetic resonance imaging [β −0.371; P <.01] in AD cases. Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.

AB - Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders. Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls. All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease. Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD. We found significant associations between macular thickness and global cortical atrophy [β −0.358; P =.01] and parietal cortical atrophy on magnetic resonance imaging [β −0.371; P <.01] in AD cases. Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067274196&origin=inward

U2 - 10.1016/j.dadm.2019.05.002

DO - 10.1016/j.dadm.2019.05.002

M3 - Article

VL - 11

SP - 463

EP - 471

JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

SN - 2352-8729

ER -